Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C et al (2022) CBTRUS Statistical Report: primary brain and other Central Nervous System tumors diagnosed in the United States in 2015–2019. Neuro-Oncol 24:v1–95. https://doi.org/10.1093/neuonc/noac202

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang S-Y, Park C-K, Park S-H, Kim DG, Chung YS, Jung H-W (2008) Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features. J Neurol Neurosurg Psychiatry 79:574–580. https://doi.org/10.1136/jnnp.2007.121582

Article  PubMed  Google Scholar 

Sahm F, Reuss DE, Giannini C (2018) WHO 2016 classification: changes and advancements in the diagnosis of miscellaneous primary CNS tumours. Neuropathol Appl Neurobiol 44:163–171. https://doi.org/10.1111/nan.12397

Article  CAS  PubMed  Google Scholar 

Cornelius JF, Slotty PJ, Steiger HJ, Hänggi D, Polivka M, George B (2013) Malignant potential of skull base versus non-skull base meningiomas: clinical series of 1,663 cases. Acta Neurochir (Wien) 155:407–413. https://doi.org/10.1007/s00701-012-1611-y

Article  PubMed  Google Scholar 

Maggio I, Franceschi E, Tosoni A, Nunno VD, Gatto L, Lodi R et al (2021) Meningioma: not always a benign Tumor. A review of advances in the treatment of meningiomas. CNS Oncol 10:CNS72. https://doi.org/10.2217/cns-2021-0003

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goldbrunner R, Minniti G, Preusser M, Jenkinson MD, Sallabanda K, Houdart E et al (2016) EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol 17:e383–391. https://doi.org/10.1016/S1470-2045(16)30321-7

Article  PubMed  Google Scholar 

Pepe F, Pisapia P, Del Basso de Caro ML, Conticelli F, Malapelle U, Troncone G et al (2020) Next generation sequencing identifies novel potential actionable mutations for grade I meningioma treatment. Histol Histopathol 35:741–749. https://doi.org/10.14670/HH-18-195

Article  CAS  PubMed  Google Scholar 

Nassiri F, Liu J, Patil V, Mamatjan Y, Wang JZ, Hugh-White R et al (2021) A clinically applicable integrative molecular classification of meningiomas. Nature 597:119–125. https://doi.org/10.1038/s41586-021-03850-3

Article  CAS  PubMed  Google Scholar 

Sahm F, Schrimpf D, Stichel D, Jones DTW, Hielscher T, Schefzyk S et al (2017) DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol 18:682–694. https://doi.org/10.1016/S1470-2045(17)30155-9

Article  CAS  PubMed  Google Scholar 

Youngblood MW, Miyagishima DF, Jin L, Gupte T, Li C, Duran D et al (2021) Associations of meningioma molecular subgroup and Tumor recurrence. Neuro-Oncol 23:783–794. https://doi.org/10.1093/neuonc/noaa226

Article  CAS  PubMed  Google Scholar 

Patel AJ, Wan Y-W, Al-Ouran R, Revelli J-P, Cardenas MF, Oneissi M et al (2019) Molecular profiling predicts meningioma recurrence and reveals loss of DREAM complex repression in aggressive tumors. Proc Natl Acad Sci U S A 116:21715–21726. https://doi.org/10.1073/pnas.1912858116

Article  CAS  PubMed  PubMed Central  Google Scholar 

Choudhury A, Magill ST, Eaton CD, Prager BC, Chen WC, Cady MA et al (2022) Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities. Nat Genet 54:649–659. https://doi.org/10.1038/s41588-022-01061-8

Article  CAS  PubMed  PubMed Central  Google Scholar 

Driver J, Hoffman SE, Tavakol S, Woodward E, Maury EA, Bhave V et al (2022) A molecularly integrated grade for meningioma. Neuro-Oncol 24:796–808. https://doi.org/10.1093/neuonc/noab213

Article  CAS  PubMed  Google Scholar 

Choudhury A, Chen WC, Lucas C-HG, Bayley JC, Harmanci AS, Maas SLN et al (2023) Hypermitotic meningiomas harbor DNA methylation subgroups with distinct biological and clinical features. Neuro-Oncol 25:520–530. https://doi.org/10.1093/neuonc/noac224

Article  CAS  PubMed  Google Scholar 

Raleigh D, Chen W, Choudhury A, Youngblood M, Polley M-Y, Lucas C-H et al (2023) Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses. Res Sq. https://doi.org/10.21203/rs.3.rs-2663611/v1. rs.3.rs-2663611

Article  PubMed  PubMed Central  Google Scholar 

Brastianos PK, Horowitz PM, Santagata S, Jones RT, McKenna A, Getz G et al (2013) Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet 45:285–289. https://doi.org/10.1038/ng.2526

Article  CAS  PubMed  PubMed Central  Google Scholar 

Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Özduman K et al (2013) Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 339:1077–1080. https://doi.org/10.1126/science.1233009

Article  CAS  PubMed  PubMed Central  Google Scholar 

Smith MJ, O’Sullivan J, Bhaskar SS, Hadfield KD, Poke G, Caird J et al (2013) Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas. Nat Genet 45:295–298. https://doi.org/10.1038/ng.2552

Article  CAS  PubMed  Google Scholar 

Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C et al (1993) Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 363:515–521. https://doi.org/10.1038/363515a0

Article  CAS  PubMed  Google Scholar 

Clark VE, Harmancı AS, Bai H, Youngblood MW, Lee TI, Baranoski JF et al (2016) Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas. Nat Genet 48:1253–1259. https://doi.org/10.1038/ng.3651

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bi WL, Santagata S (2022) Skull Base tumors: Neuropathology and Clinical implications. Neurosurgery 90:243. https://doi.org/10.1093/neuros/nyab209

Article  PubMed  Google Scholar 

Bujko M, Kober P, Tysarowski A, Matyja E, Mandat T, Bonicki W et al (2014) EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas. Oncol Lett 7:2019–2022. https://doi.org/10.3892/ol.2014.2042

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alliance for Clinical Trials in Oncology (2023) Phase II trial of SMO/ AKT/ NF2/CDK inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2/CDK pathway mutations. clinicaltrials.gov

Sahm F, Schrimpf D, Olar A, Koelsche C, Reuss D, Bissel J et al (2015) TERT promoter mutations and risk of recurrence in Meningioma. JNCI J Natl Cancer Inst 108:djv377. https://doi.org/10.1093/jnci/djv377

Article  CAS  PubMed  Google Scholar 

Wang JZ, Patil V, Liu J, Dogan H, Tabatabai G, Yefet LS et al (2023) Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomas. Acta Neuropathol (Berl) 146:145–162. https://doi.org/10.1007/s00401-023-02571-3

Article  CAS  PubMed  Google Scholar 

Graillon T, Tabouret E, Chinot O (2021) Chemotherapy and targeted therapies for meningiomas: what is the evidence? Curr Opin Neurol 34:857. https://doi.org/10.1097/WCO.0000000000001002

Article  CAS  PubMed  Google Scholar 

Dankner M, Rose AAN, Rajkumar S, Siegel PM, Watson IR (2018) Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. Oncogene 37:3183–3199. https://doi.org/10.1038/s41388-018-0171-x

Article  CAS  PubMed  Google Scholar 

Jarkowski A, Khushalani NI (2014) BRAF and beyond: tailoring strategies for the individual Melanoma patient. J Carcinog 13:1. https://doi.org/10.4103/1477-3163.126759

Article  CAS  PubMed  PubMed Central  Google Scholar 

Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954. https://doi.org/10.1038/nature00766

Article  CAS  PubMed  Google Scholar 

Matallanas D, Birtwistle M, Romano D, Zebisch A, Rauch J, von Kriegsheim A et al (2011) Raf family kinases: old dogs have learned new tricks. Genes Cancer 2:232–260. https://doi.org/10.1177/1947601911407323

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pan J-H, Zhou H, Zhu S-B, Huang J-L, Zhao X-X, Ding H et al (2018) Development of small-molecule therapeutics and strategies for targeting RAF kinase in BRAF-mutant Colorectal cancer. Cancer Manag Res 10:2289–2301. https://doi.org/10.2147/CMAR.S170105

Article  CAS  PubMed  PubMed Central  Google Scholar 

Leonetti A, Facchinetti F, Rossi G, Minari R, Conti A, Friboulet L et al (2018) BRAF in non-small cell Lung cancer (NSCLC): pickaxing another brick in the wall. Cancer Treat Rev 66:82–94. https://doi.org/10.1016/j.ctrv.2018.04.006

Article  CAS  PubMed  Google Scholar 

Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI et al (2003) Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 88:4393–4397. https://doi.org/10.1210/jc.2003-030305